TARA stock icon

Protara Therapeutics
TARA

$2.30
7.5%

Market Cap: 47.4M

 

About: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Employees: 27

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

125% more capital invested

Capital invested by funds: $8.17M [Q4 2023] → $18.3M (+$10.2M) [Q1 2024]

14% more call options, than puts

Call options by funds: $92K | Put options by funds: $81K

13% more funds holding

Funds holding: 30 [Q4 2023] → 34 (+4) [Q1 2024]

1.66% more ownership

Funds ownership: 38.33% [Q4 2023] → 39.99% (+1.66%) [Q1 2024]

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$23
900%
upside
Avg. target
$25
976%
upside
High target
$30
1,204%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
900%upside
$23
Buy
Reiterated
6 May 2024
Oppenheimer
Leland Gershell
1,204%upside
$30
Outperform
Maintained
22 Apr 2024
HC Wainwright & Co.
Andrew Fein
900%upside
$23
Buy
Maintained
8 Apr 2024
HC Wainwright & Co.
Andrew Fein
900%upside
$23
Buy
Reiterated
14 Mar 2024

Financial journalist opinion